FISV enters the back half of August with an unusual combination: the stock is still down sharply from its highs, yet insiders are buying aggressively and short sellers are quietly retreating — a divergence that makes the current setup worth watching closely.
The insider story is the most compelling angle this week. Seven separate insiders bought shares between mid-June and early August, including CFO Paul Todd, who purchased just over 10,000 shares at $49.70 in June, and Chief Administration Officer Adam Rosman, who added 10,150 shares at $49.33. An independent director added another 10,000 shares on August 7 at $51.95 — after earnings. Net insider buying over the past 90 days totals approximately $2.24 million across 44,781 shares. The cluster is notably broad: it spans C-suite executives, the CAO, and multiple board members, all buying within a tight price range around $49–$52. That kind of coordinated accumulation at depressed prices is a data point that rarely goes unnoticed by the Street.
Short positioning tells a story that supports the insider read rather than contradicting it. Short interest has fallen roughly 15% over the past month, dropping from above 23 million shares in mid-July to around 18.4 million — now at 3.4% of the free float, a level that is elevated but not extreme. Borrow costs have more than halved in a week, falling to 0.28% from around 0.50%, their lowest level in the 30-day window. Availability remains extraordinarily loose at over 2,000% — meaning the lending pool holds many times more shares than are currently borrowed — so there is no structural squeeze pressure. The ORTEX short score of 35 places FISV roughly in the middle of the universe; this is not a heavily contested name from a short-selling perspective.
Options positioning cuts the other direction, and that contrast is worth naming explicitly. The put/call ratio has climbed to 0.98, close to its 52-week high of 0.98 set just a day earlier on August 13, and running well above its 20-day average of 0.83 — roughly 1.3 standard deviations above the norm. That is notably more defensive hedging than the stock has seen for most of the year. The sharp shift in PCR happened immediately after the August 6 earnings print, which delivered a one-day drop of 3.1% before recovering 2.6% over the following five days — a pattern that appears to have left options traders more cautious even as the stock clawed back ground.
The Street has adjusted targets downward but kept its guns, and that tension with current price creates an interesting backdrop. The mean price target across analysts is $62.18, against a close of $54.39 — implying roughly 14% upside from current levels. However, JP Morgan maintained Neutral while cutting its target from $62 to $60, and Barclays held Equal-Weight while trimming to $52, essentially in-line with the current price. RBC Capital's Outperform rating with a $65 target represents the bull case. The analyst consensus is "Hold" with 26 Hold ratings dominating the count. Valuation multiples add nuance: the PE ratio has risen to 7.0 over the past month while EV/EBITDA has also expanded slightly, suggesting the market is paying a touch more for the earnings stream even as growth concerns persist. The factor score for forward EPS growth ranks at the 82nd percentile — the strongest single factor in the profile — while near-term EPS momentum scores are weak at the 12th and 13th percentiles over 30 and 90 days respectively.
Among peers, GPN and PAY both surged more than 8% on the week while FISV gained around 3.8%, reinforcing the year-to-date underperformance pattern flagged in recent coverage. FIS and TOST were both weaker on the day Friday, suggesting sector-wide caution into the weekend rather than FISV-specific selling.
The next scheduled earnings date is November 6 — the key question between now and then is whether the insider buying cluster and the short-covering trend can build enough momentum to close the gap between where the stock trades and where even the more cautious analysts have their targets.
See the live data behind this article on ORTEX.
Open FISV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
